The following protocols represent commonly reported approaches, though individual response varies and conservative starting doses remain prudent
The initial commercial release of the BPC-157 transdermal patch is described as being planned through The Precision Peptide Company website, located at www.precisionpeptidecompany.com, which suggests an initial direct-to-consumer e-commerce approach
Advanced protocols with the 60 mg vial Beyond standard titration, the 60 mg vial supports several advanced dosing strategies that smaller vials cannot practically accommodate
NRF2 also cooperates with components of the transcriptional machinery (i.e., MED16) (Sekine et al, 2016), chromatin remodelers (i.e., BRG1) (Zhang et al, 2006) and chromatin-modifying enzymes (i.e., CBP) (Katoh et al, 2001) to drive target gene expression
But they do not rebuild tissue